Status: Not yet recruiting
A Phase 1/2a Study of K-1728 in Advanced Solid Tumors
This first-in-human, open-label, multicenter study evaluates K-1728 administered as monotherapy and in combination in participants with advanced or metastatic solid tumors. The study assesses the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of K-1728.
Participants needed: 110
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: KymaThera, Inc.Updated: Oct 6, 2026
Eligibility criteria
Adults with advanced or metastatic solid tumors who are able to provide consent [+3]
Active or untreated central nervous system disease [+4]